OBJECTIVE: The effects of celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, on HeLa cervical cancer cell growth and radiosensitivity were investigated. METHODS: Cytotoxicity was quantified using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay and effects on radiosensitivity were assessed using the lethal dose, quasithreshold dose, fraction surviving after 2 Gy irradiation and the radiosensitization ratio (SER, based on average lethal dose) determined using a single-hit multitarget model. RESULTS: Celecoxib inhibited HeLa cell proliferation in a concentration-and time-dependent
Introduction
Cervical cancer, a common gynaecological malignancy, is a serious threat to women's health. 1 Radiotherapy is the main treatment 2 and factors influencing its effectiveness, such as cervical characteristics, tumour radiosensitivity and irradiation sensitization therapy, have been the subject of much research. 3 Cyclo-oxygenase 2 (COX-2), the inducible isoform of cyclo-oxygenase, catalyses the rate-limiting step of prostaglandin synthesis from arachidonic acid. Various prostaglandins are produced in a cell type-specific manner and elicit cellular functions by signalling through G-protein-coupled membrane receptors and the nuclear receptor peroxisome proliferator-activated receptor. The reaction of COX-2 with arachidonic acid perturbs the level of free intracellular arachidonic acid and subsequently affects cellular function. 4 COX-2 has also been implicated in the progression and angiogenesis of cancers. 5 Celecoxib, a COX-2-selective inhibitor, is the only non-steroidal anti-inflammatory drug approved for adjuvant treatment of patients with familial adenomatous polyposis and has been shown to enhance tumour radiosensitivity. 6 -8 In common with other selective COX-2 inhibitors, celecoxib shows reduced risk of upper gastrointestinal ulcer complications 9 and protects normal cells during irradiation. 10 The present study examined the effect of celecoxib on the growth and radiosensitivity of HeLa cervical cancer cells. In addition, because COX-2 expression has previously been shown to be associated with vascular endothelial growth factor C (VEGF-C) expression in human cervical cancer, 11 the mechanisms of action of celecoxib were investigated by measuring its effects on the expression of these two proteins.
Materials and methods

EFFECT OF CELECOXIB ON CELL PROLIFERATION
HeLa cells (a gift from Huazhong University of Science and Technology, Wuhan, China) were suspended in RPMI-1640 medium at a concentration of 1 × 10 4 cells/ml and 90 µl of the suspension was added to each well of a 96-well plate. The cells were then cultured in medium alone (control) or with celecoxib (Pfizer, New York, NY, USA) at final concentrations of 5, 10, 20, 40, 50, 80, 100 and 160 µmol/l at 37°C under a saturated atmosphere containing 5% carbon dioxide for 24, 48, 72 or 96 h. Then, 20 µl of a solution of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) was added. After mixing, the plates were incubated for 4 h and 150 µl dimethylsulphoxide was added and mixed by shaking for 10 min. Absorbance was measured at 420 nm using a Spectra microplate reader (Molecular Devices, Sunnyvale, CA, USA) and adjusted to the value of a blank control well (no cells). For each sample, the mean of four replicate wells was calculated. The number of dead cells floating on the culture surface was assessed under the microscope.
EFFECT OF CELECOXIB ON RADIOSENSITIZATION
HeLa cells in the logarithmic phase were adjusted to a concentration of 1 × 10 4 cells/ml, plated into six-well plates and cultured for 24 h. Cells were then left untreated (controls), exposed to irradiation, or exposed to irradiation and treated with 20 or 40 µmol/l celecoxib for 72 h before irradiation. Radiation doses were 0 (100 cells/well), 2 (150 cells/well), 4 (350 cells/well), 6 (700 cells/well) or 8 Gy (3500 cells/well), applied using 6 MV X-irradiation at the rate of 2 Gy/min. There were three replicates for each dose. During radiation exposure the cells were covered with a 1.5 cm acrylic plate placed 100 cm from the source. The cells were then incubated for 12 days, fixed for 30 min in 4% paraformaldehyde and stained with crystal violet. The number of clones was counted under low-power magnification (× 100). Each experiment was performed three times to determine the survival fraction. To assess the effect of different sequences of celecoxib and radiation treatment, three additional groups of cells were treated with 40 µmol/l celecoxib: (i) for 72 h before radiation exposure; (ii) for 72 h from the time of radiation exposure; or (iii) for 72 h starting 24 h after radiation exposure. The radiation doses 0, 2, 4, 6 and 8 Gy were used in each of these three sequences.
To take account of the cytotoxic effect of celecoxib, the pooled adherence rate of the groups treated with celecoxib and exposed to radiation was calculated relative to the nonirradiated celecoxib-only group, and the adherence rate of the cells exposed to radiation alone was calculated relative to that of the control cells (not treated with celecoxib).
For the different drug concentrations and treatment administration sequences, the cell survival rate and the following radiosensitivity parameters were calculated using a singlehit multitarget detection model: 12 mean lethal dose of radiation (D 0 , Gy), the quasithreshold dose (D q , Gy), the fraction of cells surviving after 2 Gy irradiation (SF 2 ) and the radiosensitization ratio (sensitization enhancement ratio, SER), calculated as D 0 for the control group divided by D 0 for the treatment group.
Survival curves were fitted using MATLAB ® (MathWorks ® , Natick, MA, USA).
COX-2 AND VEGF-C IMMUNOCYTOCHEMISTRY
HeLa cells in the logarithmic phase of growth were adjusted to a concentration of 1 × 10 4 cells/ml and drops (0.5 -1.0 ml) of cell suspension were placed on coverslips on each well of six-well plates. Negative control and control cells were then left untreated in normal RPMI-1640 medium; other groups of cells were treated with 2 Gy irradiation without celecoxib pretreatment or were treated with 2 Gy irradiation after 72 h of pretreatment with 40 µmol/l celecoxib, and then cultured for 24 h. The experimental protocol followed the instructions for the universal streptavidin-peroxidase immunohisto chemistry kit (Beijing Zhongshan Golden Bridge Biotechnology, Beijing, China).
Cells were fixed in 4% paraformaldehyde for 30 min and subjected to two-step immuno cyto chemistry using the SP immuno histo chemistry kit with ready-touse anti-COX-2 or anti-VEGF-C monoclonal antibodies (Beijing Zhongshan Golden Bridge Biotechnology) and developed using the chromogen 3,3′-diaminobenzidine (DAB; Beijing Zhongshan-Golden Bridge Biotechnology). The cells were then counterstained with haematoxylin and the percentages of COX-2-and VEGF-C-positive cells, detected by the presence of yellow or brown cytoplasmic granules, were determined from 10 fields of view at 400 × magnification for each sample. Specimens were scored on the basis of staining intensity and the percentage of positively stained cells. Both variables were scored on a scale of 0 -3. Staining intensity was scored as: negative, 0; weakly positive, 1; moderately positive, 2; strongly positive, 3. The percentage of positively staining cells was scored as: no positively stained cells, 0; positive staining in < 30% of cells, 1; positive staining in 30 -70% of cells, 2; positive staining in ≥ 70% of cells, 3. 13 Overall positivity score was the product of the two scores: overall score 0 (-), overall score 2 (+), overall score 3/4 (++) , overall score 6/9 (+++).
STATISTICAL ANALYSES
Results were reported as mean ± SD and compared using the χ 2 -test and analysis of variance. A P-value < 0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS ® statistical analysis software, version 17.0 (SPSS Inc., Chicago, IL, USA).
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Results
EFFECT OF CELECOXIB ON CELL PROLIFERATION
Morphological changes were observed in HeLa cells in response to celecoxib. Untreated HeLa cells were adherent and showed normal triangular or spindle morphology and membrane integrity, with no detached cells or cell debris. After exposure to celecoxib for 24 h, floating dead cells were observed and cell growth was slowed compared with untreated controls. After 72 h, cell number was markedly reduced and the proportion of floating dead cells gradually increased over time indicating that celecoxib exerted cytotoxic effects.
Celecoxib at concentrations < 40 µmol/l had no significant effect on cell proliferation (growth) up to 72 h of culture; however, at concentrations between 40 and 100 µmol/l celecoxib significantly inhibited cell growth in a time-and concentration-dependent manner, with a half-maximal inhibitory concentration at 72 h of 44 µmol/l (P < 0.05) ( Fig. 1 ). Significant cell growth inhibition was also observed with 80, 100 and 160 µmol/l celecoxib treatment at all time points compared with control (P < 0.05); 160 µmol/l celecoxib led to an almost complete absence of cell viability at all time points ( Fig. 1 ).
EFFECT OF CELECOXIB CONCENTRATION ON RADIOSENSITIZATION
Cell survival curves generated using the single-hit multitarget detection model are shown in Fig. 2 . Increasing concentrations of celecoxib decreased the ability of HeLa cells to repair radiation-induced sublethal injury. The radiosensitivity parameters D 0 , D q and SF 2 were significantly reduced in irradiated cells pretreated with celecoxib at 20 or 40 µmol/l compared with cells receiving irradiation alone (P < 0.05) ( Table  1) . Radiosensitization of HeLa cells by celecoxib was concentration-dependent: the SER of cells pretreated with 40 µmol/l celecoxib was higher than that of cells pretreated with 20 µmol/l celecoxib (increased from 2.01 to 2.41). The SER values were similar at different irradiation doses (data not shown). 
TREATMENT SEQUENCE AND RADIOSENSITIZATION
Cell survival curves generated for the different treatment schedules showed that the treatment sequence affected celecoxibinduced radiosensitivity (Fig. 3) . The radiosensitivity parameters D 0 , D q and SF 2 were significantly lower in cells treated with celecoxib combined with irradiation than in those treated with irradiation alone (P < 0.05). The differences observed between the SER of HeLa cells treated with 40 µmol/l celecoxib before, during and after irradiation, indicated that pretreatment with celecoxib had a synergistic effect on radiosensitivity (Table 1) .
EFFECT OF CELECOXIB ON COX-2 AND VEGF-C EXPRESSION
No COX-2 or VEGF-C immunoreactivity was observed in the negative control group of HeLa cells (Fig. 4A ). Approximately 50% of the control cells (no celecoxib, no irradiation) expressed cytoplasmic COX-2 (Fig. 4B ). In the samples exposed to 2 Gy irradiation without celecoxib pretreatment, 90% of the cells demonstrated strongly positive COX-2 cytoplasmic staining (dark brown in Fig. 4C ). In contrast, only 10% of the cells pretreated for 72 h with 40 µmol/l celecoxib stained for COX-2 and the staining was only weak (Fig. 4D) .
Approximately 58% of the control cells expressed cytoplasmic VEGF-C (Fig. 4E ). In the samples exposed to 2 Gy irradiation without celecoxib pretreatment, 92% of the cells showed strongly positive VEGF-C cytoplasmic staining (Fig. 4F ), whereas only 9% of the cells pretreated for 72 h with 40 µmol/l celecoxib before radiation exposure stained for VEGF-C and the staining was only weak (Fig. 4G) . The protein expression of COX-2 in the different treatment regimes was similar to that of VEGF-C ( Table 2) . 
Discussion
Radiotherapy is the primary treatment for cervical cancer. In recent years, the proportion of radioresistant cervical adenocarcinomas with recurrence and distant metastasis occurring after treatment has increased, 14 and radiosensitizing agents have become a major focus of research. Chen et al. 14 demonstrated that COX-2 expression in cervical adenocarcinoma was significantly greater than in cervical squamous cell carcinoma, so adenocarcinoma HeLa cells were chosen for the present study. Ma et al. 15 reported that 16 observed that celecoxib had a significant inhibitory effect in CNE-2Z nasopharyngeal carcinoma cells, with a half-maximal inhibitory concentration (IC 50 ) at 72 h of 100 µmol/l, and that celecoxib reduced the expression of COX-2 mRNA compared with the control group, as shown by reverse transcriptionpolymerase chain reaction. The present study demonstrated a time-and concentration-dependent inhibitory effect of celecoxib on HeLa cell growth, with a 72 h IC 50 of 44 µmol/l, suggesting that cancer cells from different tissues have different sensitivities to celecoxib; this may be related to differences in cell doubling time or the cell cycle ratio. In the present study, using concentrations of celecoxib lower than the IC 50 (< 40 µmol/l), the radiosensitizing effect was dependent on concentration and treatment sequence; pretreatment with celecoxib had significantly greater effects on radiosensitivity than treatment started during or after irradiation.
The enzyme COX-2 and its prostaglandin products exert radioprotection, 17 -19 while COX-2 inhibitors have been reported to enhance tumour radiosensitivity. 6 -8 Multivariate analyses have shown that high protein expression of COX-2 is an independent predictor of poor prognosis in cancer patients. 20 -22 Increased protein expression of COX-2 in tumour cells was observed after irradiation in the present study.
Celecoxib inhibits the phosphoinositide 3-kinase/Akt/COX-2 pathway 23 and, in the present study, celecoxib treatment before irradiation increased radiosensitivity in a synergistic manner. Celecoxib reduced COX-2 protein expression in HeLa cells, indicating that COX-2 inhibitors act on molecules upstream of COX-2 to inhibit COX-2 protein expression. Reduced protein expression of COX-2 is likely to lead to reduced expression of prostaglandins, which exert a radioprotective effect and is, therefore, associated with increased radiosensitivity. Celecoxib pretreatment may also increase the number of cells in the radiosensitive G 2 /M phase, thus increasing the effectiveness of irradiation. 24 Additionally, COX-2 inhibitors are weak acids and, in vivo, may be able to penetrate tumour tissues which are usually insensitive to radiotherapy, creating a hypoxic or acid environment that increases tumour radiosensitivity. 25 Expression of COX-2 in stage IB-IIA cervical squamous cell carcinoma may have prognostic value for lymph node metastasis in tumours with extensive invasion of the lymphovascular space. 26 COX-2 is upregulated in many cancers and is associated with increased VEGF and angiogenesis, which are important targets in tumour therapy. 27 COX-2 expression, tumour progression and angiogenesis are related, suggesting that COX-2 metabolites promote 
TABLE 2:
Comparison of immunohistochemical positivity of HeLa cells for cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor C (VEGF-C) protein after pretreatment with 40 µmol/l celecoxib for 72 h followed by 2 Gy X-irradiation or irradiation alone AH Wang, XY Tian, JJ Yu et al. COX-2-and VEGF-C-dependent celecoxib radiosensitivity angiogenesis and invasion. 28 Steinauer et al. 29 observed a dosedependent increase in COX-2 following irradiation and, in the present study, increased COX-2 protein expression was seen in irradiated HeLa cells. Increased COX-2 expression after radiotherapy could lead to radioresistance, tumour recurrence and metastasis. Because COX-2 protein expression is suppressed by the COX-2 inhibitor, celecoxib, combining COX-2 inhibitors with radiation therapy has a theoretical basis and implications for clinical practice.
In the present study, celecoxib reduced protein expression of COX-2 and VEGF-C, while irradiation increased the expression of both proteins, suggesting that a reduction in COX-2 protein expression has a role in the antitumour effect of celecoxib. We in the present study, however, and Patel et al. 30 previously found that the level of inhibition of cell proliferation and the decline in the level of COX-2 protein associated with celecoxib were not closely related, suggesting that the effects of celecoxib on cell proliferation are independent of its effects on COX-2. Nuclear factor κ-light chain enhancer of activated B cells (NF-κB) may be involved in celecoxibinduced apoptosis, as a correlation has been demonstrated between increased NF-κB DNA binding activity and attenuation of the proapoptotic effect of celecoxib by an NF-κB inhibitor. 31 In addition, celecoxib downregulates Ku70 protein and inhibits DNAdependent protein kinase catalytic subunit activity, both of which form part of doublestranded DNA break repair machinery; celecoxib radiosensitivity may, therefore, be the result of DNA repair inhibition 32 and altered cell cycle distribution. 33 Desai et al. 34 observed that the VEGF-C promoter contains NF-κB binding sites, so celecoxib may reduce VEGF-C expression by inhibition of NF-κB signalling. A study by Mehar et al. 35 indicated that celecoxib acts through both COX-2dependent and COX-2-independent mechanisms.
The COX-2-independent pathways that regulate the anticancer effects of celecoxib in HeLa cells require further study.
Expression levels of COX-2 and VEGF-C have been shown to be closely related during tumour development and lymph node metastasis. 36, 37 COX-2 stimulates upregulation of VEGF-C, which binds the VEGF-3 receptor to induce lymphangiogenesis, increasing the probability of lymph node metastasis. Su et al. 38 reported that COX-2 protein expression was highly correlated with VEGF-C expression, lymphatic vessel density and other clinicopathological parameters in lung adenocarcinoma, and that COX-2 up-regulated VEGF-C via the EP 1 /Src/human epidermal growth factor receptor 2 (HER-2/Neu) signalling pathway, leading to lymphangiogenesis.
In conclusion, the present study has demonstrated that celecoxib radiosensitizes HeLa cells in concentration-and treatment sequence-dependent manners, through a mechanism related to the down-regulation of COX-2 and VEGF-C. Irradiation and COX-2 inhibition were found to have a synergistic inhibitory effect on tumour cell proliferation and tumour angiogenesis; the combination of radiotherapy with COX-2 inhibitors therefore represents a promising approach towards improving the therapeutic efficacy of cervical cancer treatment.
